Phase II and Phase III attrition rates 2011–2012

John Arrowsmith(Thomson Reuters (United Kingdom)), J. Philip Miller(Thomson Reuters (United Kingdom))
Nature Reviews Drug Discovery
August 1, 2013
10.1038/nrd4090
Cited by 689Open Access
Full Text

Abstract

Related Papers

No related papers found

Powered by citation graph analysis